Last reviewed · How we verify
NCT05895110
To Evaluate the Immunogenicity and Safety of Sequential Booster Immunization of Recombinant Novel Coronavirus Vaccine (CHO Cells) for SARS-CoV-2
NA trial testing Recombinant Novel Coronavirus vaccine (CHO Cells) in COVID-19 in 240 participants. Completed in 19 November 2022.
19 November 2022
Quick facts
| Lead sponsor | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 240 |
| Start date | 29 April 2022 |
| Primary completion | 19 November 2022 |
| Estimated completion | 19 November 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Recombinant Novel Coronavirus vaccine (CHO Cells) — full drug profile →
Conditions studied
- COVID-19 — all drugs for COVID-19 →
Sponsor
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. — full company profile →
Who can join
Adults 3 to 17, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
An open experimental design was used in this study, and 240 subjects were planned to be enrolled. To evaluate the immunogenicity and safety of recombinant Novel Coronavirus vaccine (CHO cells) after sequential intensification in populations vaccinated with two doses of marketed Novel Coronavirus inactivated vaccine.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial.
Huang T, Hu Q, Zhou X, Yang H, et al · · 2024 · cited 1× · PMID 38641791 · DOI 10.1186/s12879-024-09293-1
Verify or expand the search:
- PubMed search for NCT05895110
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. trials
Trials by the same sponsor.
- NCT06747455 — BCG for Therapeutic Use Phase Ⅲ Clinical Trial · Phase 3 · recruiting
- NCT06524947 — Clinical Trial of Protective Efficacy of Quadrivalent Recombinant Norovirus Vaccine (Pichia Pastoris) · Phase 3 · active not recruiting
- NCT06100653 — BCG for Therapeutic Use Phase I Clinical Trial · Phase 1 · completed
- NCT06025812 — Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells) · NA · unknown
- NCT05899179 — Clinical Study of Recombinant Mycobacterium Tuberculosis Fusion Protein for 65-year-olds and Above · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05895110 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- Last refreshed: 8 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05895110.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing